NASA has decided that humans are going back to the Moon. That’s great! Before that actually happens, a whole bunch of other things have to happen, and excitingly, many of those things involve robots. As a sort of first-ish step, NASA is developing a new lunar rover called VIPER (Volatiles Investigating Polar Exploration Rover). VIPER’s job is to noodle around the permanently shaded craters at the Moon’s south pole looking for water ice, which can (eventually) be harvested and turned into breathable air and rocket fuel.
The DNA molecule inside the nucleus of any human cell is more than six feet long. To fit into such a small space, it must fold into precise loops that also govern how genes are turned on or off. New research indicates that ‘jumping genes’ play a surprising role in stabilizing the 3D folding patterns of the DNA molecule inside the cell’s nucleus.
Smaller is better when it comes to microchips, researchers said, and by using 3D components on a standardized 2D microchip manufacturing platform, developers can use up to 100 times less chip space. A team of engineers has boosted the performance of its previously developed 3D inductor technology by adding as much as three orders of magnitudes more induction to meet the performance demands of modern electronic devices.
For decades, it’s been understood that water repellency is needed for surfaces to shed condensation buildup – like the droplets of water that form in power plant condensers to reduce pressure. New research shows that the necessity of water repellency is unclear and that the slipperiness between the droplets and solid surface appears to be more critical to the clearing of condensation. This development has implications for the costs associated with power generation and technologies like de-icing surfaces for power lines and aircraft.
Merck KGaA spinout iOnctura has raised a €15 million ($17 million) series A round to support an early-phase solid tumor trial. The company is gearing up to generate data on PI3Kδ inhibitor IOA-244 in humans while hustling a second candidate through IND-enabling studies.
Roche’s risdiplam has come through another late-phase test, triggering improvements in the motor skills of infants with type 1 spinal muscular atrophy. The clinical success comes months before the FDA is set to decide whether to approve the survival motor neuron-2 splicing modifier.
That would accelerate the company’s “decarbonization” plan by more than a decade.
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the pricing of its public offering of 4,300,000 shares of its common stock at a price to the public of $21.50 per share.
Genentech announced positive topline results from its pivotal Part 2 of the FIREFISH study looking at risdiplam in infants aged 1-7 months with Type 1 SMA.
Companies from across the globe provide updates on their businesses and pipelines.